UCB (OTCMKTS:UCBJY) Sets New 12-Month High – What’s Next?

UCB SA (OTCMKTS:UCBJY – Get Free Report) shares reached a new 52-week high on Tuesday . The company traded as high as $98.65 and last traded at $98.59, with a volume of 9802 shares traded. The stock had previously closed at $97.31.

UCB Price Performance

The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The stock’s 50-day moving average price is $92.17 and its 200-day moving average price is $80.80.

UCB Company Profile

(Get Free Report)

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

Read More

• Five stocks we like better than UCB
• How Investors Can Find the Best Cheap Dividend Stocks
• Palantir Cracks $50, Is There Still Time to Get on Board?
• The Basics of Support and Resistance
• Insider Buying Signals Upside for These 3 Stocks
• Why Are Stock Sectors Important to Successful Investing?
• These 2 Big Players Are Set to Compete With Elon Musk’s Starlink